Vaxcyte, Inc.

NasdaqGS PCVX

Vaxcyte, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 2.45 B

Vaxcyte, Inc. Net Cash Used Provided By Financing Activities is USD 2.45 B for the Trailing 12 Months (TTM) ending September 30, 2024, a 89.09% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Vaxcyte, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 1.29 B, a 505.48% change year over year.
Vaxcyte, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 213.67 M, a 2,126.40% change year over year.
Vaxcyte, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 9.60 M, a -97.69% change year over year.
Vaxcyte, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 415.67 M.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: PCVX

Vaxcyte, Inc.

CEO	Mr. Grant E. Pickering M.B.A.
IPO Date	June 12, 2020
Location	United States
Headquarters	825 Industrial Road
Employees	254
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Key trends

Past 5 years